Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Skye Fund III Issued An Open Letter To SomaLogic's Shareholders Regarding Its Opposition To The Company's Proposed Merger With Standard BioTools And Its Intention To Vote Against The Proposed Merger

Author: Benzinga Newsdesk | December 20, 2023 10:05am

Believes that the Proposed Merger Grossly Undervalues SomaLogic and Ignores its Revolutionary Products, Considerable Cash Position, and Strong Balance Sheet

 

Iterates that SomaLogic can Thrive as a Standalone Enterprise and Does Not Need Standard BioTools to Thrive

Expresses Serious Concerns with Other Aspects of the Proposed Merger, including Potential Conflicts of Interest

Posted In: LAB SLGC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist